Investigates siloxanes as alternatives to PFAS in essential applications, indicating potential regulatory compliance benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Donahue-Boyle et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: